TNF Pharmaceuticals, Inc.
$5.20+48.15%(+$1.69)
TickerSpark Score
46/100
100
Valuation
20
Profitability
15
Growth
64
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TNFA research report →
52-Week Range1% of range
Low $3.24
Current $5.20
High $195.00
Companytnfpharma.com
TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms.
- CEO
- Mitchell Glass
- IPO
- 2014
- Employees
- 2
- HQ
- New York City, NY, US
Price Chart
-97.45% · this period
Valuation
- Market Cap
- $9.18M
- P/E
- -2.76
- P/S
- 0.00
- P/B
- 1.37
- EV/EBITDA
- -0.80
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -59.95%
- ROIC
- -26.68%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-23,359,334 · -483.99%
- EPS
- $-1115.00 · -109.19%
- Op Income
- $-10,168,790
- FCF YoY
- 30.85%
Performance & Tape
- 52W High
- $195.00
- 52W Low
- $3.24
- 50D MA
- $7.03
- 200D MA
- $33.82
- Beta
- 2.28
- Avg Volume
- 1.68M
Get TickerSpark's AI analysis on TNFA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 25 | RAUCH GARY M | other | 75,000 |
| Apr 17, 25 | RHODES IAN | other | 25,000 |
| Apr 17, 25 | Glass Mitchell | other | 125,000 |
Our TNFA Coverage
We haven't published any research on TNFA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TNFA Report →